Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
florbetazine [18F]
- Development stage
- Unknown
- Lead developer
- HighTech Atom
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Florbetazine [18F] is a fluorine-18 labeled radiopharmaceutical developed by Beijing Atom High-Tech Co., Ltd. as a diagnostic imaging agent for positron emission tomography (PET). It is a small molecule tracer designed to specifically bind to beta-amyloid (Aβ) plaques in the brain, which are a primary pathological hallmark of Alzheimer's disease (AD). By enabling the non-invasive visualization and quantification of amyloid burden, florbetazine [18F] assists clinicians in the early diagnosis of Alzheimer's disease and the evaluation of patients presenting with mild cognitive impairment (MCI). The drug is currently undergoing Phase 3 clinical trials in China to support its regulatory approval as a diagnostic tool for neurodegenerative amyloidosis.
- Other names
- 18F-florbetazineflorbetazine F-18氟贝他嗪
02
Targets
Amyloid-beta aggregate (N-terminal epitope)TTR amyloid fibril (Transthyretin amyloid fibril)AL (Amyloid light-chain protein)
Beyond the preview
Go deeper on florbetazine [18F].
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on florbetazine [18F].